Biological Products, (No Diagnostic Substances) · CIK 1620463
LeonaBio develops novel therapeutics for treatment-resistant metastatic breast cancer and ALS
Comparable business profile · signals at a glance
In the 90 days to Mar 4, 2026: 5 sold $99K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Litton Mark JamesPRESIDENT and CEO | Sell | 5,156 | $5.37 | $28K |
| Mar 4, 2026 | San Martin JavierCHIEF MEDICAL OFFICER | Sell | 1,720 | $5.37 | $9K |
| Mar 4, 2026 | Church KevinCHIEF SCIENTIFIC OFFICER | Sell | 1,359 | $5.37 | $7K |
| Mar 4, 2026 | Worthington MarkGENERAL COUNSEL and CCO | Sell | 1,328 | $5.37 | $7K |
| Mar 4, 2026 | Renninger RobertCHIEF FINANCIAL OFFICER | Sell | 906 | $5.37 | $5K |
| Jan 2, 2026 | Litton Mark JamesPresident and CEO | Sell | 2,586 | $6.88 | $18K |
| Jan 2, 2026 | San Martin JavierCHIEF MEDICAL OFFICER | Sell | 1,644 | $6.88 | $11K |
| Jan 2, 2026 | Church KevinCHIEF SCIENTIFIC OFFICER | Sell | 876 | $6.88 | $6K |
| Jan 2, 2026 | Worthington MarkGeneral Counsel and CCO | Sell | 876 | $6.88 | $6K |
| Jan 2, 2026 | Renninger RobertChief Financial Officer | Sell | 297 | $6.88 | $2K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.